APPLICATION OF ION CHANNEL BLOCKER IN TREATMENT AND/OR PREVENTION OF HEPATIC FIBROSIS
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Nov 28, 2024
app pub date -
Sep 14, 2023
filing date -
Sep 14, 2023
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
An ion channel blocker for treatment and/or prevention of hepatic fibrosis is provided. Based on the fact that the activation of hepatic stellate cells is an important link in anti-hepatic fibrosis, it is found that gliclazide has the effect of inhibiting the activation of hepatic stellate cells by in vitro and in vivo experiments. Further exploration reveals that gliclazide mainly inhibits the activation of hepatic stellate cells by inhibiting autophagy pathways, and thus the gliclazide can be used to prepare medicaments for treatment and/or prevention of hepatic fibrosis.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully